コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 device (cardiac resynchronization therapy or implantable cardioverter-defibrillator).
2 ility of life-saving preventive therapy, the implantable cardioverter defibrillator.
3 icular pacemaker, and 1 has a single chamber implantable cardioverter defibrillator.
4 F, obviating the need for primary prevention implantable cardioverter defibrillator.
5 ho are unlikely to benefit from prophylactic implantable cardioverter defibrillator.
6 e, 840 patients (42%) were implanted with an implantable cardioverter defibrillator.
7 erent implant techniques of the subcutaneous implantable cardioverter-defibrillator.
8 isk is sufficient to justify placement of an implantable cardioverter-defibrillator.
9 propriate shock following primary prevention implantable cardioverter defibrillators.
10 tly facilitated the choice of candidates for implantable cardioverter defibrillators.
11 al outcomes in patients with advanced HF and implantable cardioverter-defibrillators.
12 prognosticator and guide the optimal use of implantable cardioverter-defibrillators.
13 went a septal myectomy; 14 (25%) received an implantable cardioverter-defibrillator; 1 underwent card
14 e frequently among index-patients without an implantable cardioverter-defibrillator (10/63, 16% versu
15 med in 1,612 hospitals); 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedu
17 509 patients who had a pacemaker (58%) or an implantable cardioverter-defibrillator (42%) that was no
19 relative death risk than those receiving an implantable cardioverter-defibrillator (absolute differe
20 tening arrhythmia, implantation of pacemaker/implantable cardioverter defibrillator, acute myocardial
21 rdiac arrests and lives potentially saved by implantable cardioverter-defibrillators, all de novo imp
22 only 2 cardiac arrest survivors treated with implantable cardioverter-defibrillator alone but did not
23 , beta-blockers alone in 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%)
24 or ventricular fibrillation; and n=8 without implantable cardioverter defibrillator although with sym
25 dences of adverse events, drug continuation, implantable cardioverter defibrillator and cardiac resyn
26 , for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic
27 regarding efficacy/clinical effectiveness of implantable cardioverter defibrillators and understand w
28 45% versus 56% among patients randomized to implantable cardioverter-defibrillator and CRT with defi
29 nd impact of treatment options including the implantable cardioverter-defibrillator and heart transpl
31 among patients receiving primary prevention implantable cardioverter-defibrillator and widening QRS.
32 at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests tha
33 ejection fraction 35% or less, an automatic implantable cardioverter defibrillator, and who were ine
34 s, kidney disease, cardiac resynchronization implantable cardioverter-defibrillator, and VT storm des
40 Multivariate analysis showed that in the implantable cardioverter defibrillator arm, each 10-mm H
41 ovariates suggested for effect modification (implantable cardioverter defibrillator at baseline, left
42 with a greater increase in RWT compared with implantable cardioverter-defibrillator at 12 months (4.6
44 F or death and CRT with defibrillator versus implantable cardioverter defibrillator benefit was asses
45 herapy summarizes the existing literature on implantable cardioverter defibrillators, biventricular p
48 patients with LVEF <=35%, who are potential implantable cardioverter defibrillator candidates, treat
49 tients with AF with LVEF <=35% without prior implantable cardioverter defibrillator, cardiac resynchr
50 ng risk stratification of primary prevention implantable cardioverter defibrillators considering the
53 mporary treatment 18 experienced appropriate implantable cardioverter-defibrillator discharges, 2 und
54 patients with dilated cardiomyopathy (DCM), implantable cardioverter-defibrillators do not increase
55 all-cause mortality, composite end point of implantable cardioverter-defibrillator efficacy (arrhyth
56 ch to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a
58 bined endpoint of cardiac death, appropriate implantable cardioverter-defibrillator firing, resuscita
59 files correlated with VA events (appropriate implantable cardioverter-defibrillator firings and arrhy
60 The most frequent reason not to implant an implantable cardioverter defibrillator following WCD use
61 eceiving a cardiac resynchronization therapy implantable cardioverter defibrillator for the treatment
63 eatening arrhythmias, as well as the role of implantable cardioverter defibrillators for primary prev
64 arrhythmia and implantation of an automatic implantable cardioverter-defibrillator for prevention of
65 erion for selecting patients with DCM for an implantable cardioverter-defibrillator for primary preve
66 ation of at-risk patients and utilization of implantable cardioverter-defibrillators for prevention o
67 ion of high-risk patients who benefited from implantable cardioverter-defibrillators for sudden death
68 ODS AND Patients implanted with subcutaneous implantable cardioverter-defibrillators from 2 hospitals
70 hmic therapy and the life-saving role of the implantable cardioverter-defibrillator highlight the imp
71 iscussed before and after implantation of an implantable cardioverter defibrillator (ICD) and include
72 xercise is often avoided after receipt of an implantable cardioverter defibrillator (ICD) because of
74 valuate the survival benefit of prophylactic implantable cardioverter defibrillator (ICD) implantatio
75 previously showed a survival benefit of the implantable cardioverter defibrillator (ICD) in males wi
76 about the use of CRT in combination with an implantable cardioverter defibrillator (ICD) in patients
78 ecently, magnetic resonance (MR)-conditional implantable cardioverter defibrillator (ICD) systems hav
80 wed a significant reduction in inappropriate implantable cardioverter defibrillator (ICD) therapy in
81 and heterogeneity of LGE predict appropriate implantable cardioverter defibrillator (ICD) therapy in
82 as among patients randomized to CRT-D versus implantable cardioverter defibrillator (ICD) were compar
83 ipt of CRT with defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcom
84 he use of remote patient monitoring (RPM) of implantable cardioverter defibrillators (ICD) and all-ca
85 with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) alone are u
86 ess of CRT with defibrillator (CRT-D) versus implantable cardioverter-defibrillator (ICD) alone in CR
88 k patients eligible for a primary prevention implantable cardioverter-defibrillator (ICD) are less li
89 ave their EF reassessed 40 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.
90 ut noninducible clinical VTs based on stored implantable cardioverter-defibrillator (ICD) electrogram
91 through catheter ablation and ultimately an implantable cardioverter-defibrillator (ICD) for prompt
95 entify those patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantatio
96 The feasibility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantatio
97 have found that primary prevention use of an implantable cardioverter-defibrillator (ICD) improves su
99 nter trials have established the role of the implantable cardioverter-defibrillator (ICD) in the trea
103 g survivors of myocardial infarction with an implantable cardioverter-defibrillator (ICD) is frequent
107 Patients with an unused or malfunctioning implantable cardioverter-defibrillator (ICD) lead may ha
108 or IIa indications for CRT-D were matched to implantable cardioverter-defibrillator (ICD) patients wi
109 ackground: Long-term nonfatal outcomes after implantable cardioverter-defibrillator (ICD) placement a
110 r rehospitalization after primary prevention implantable cardioverter-defibrillator (ICD) placement i
111 EF) is recommended before primary prevention implantable cardioverter-defibrillator (ICD) placement.
112 ricular arrhythmias (VAs) and should undergo implantable cardioverter-defibrillator (ICD) placement.
114 utaneous coronary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries
115 ng the National Cardiovascular Data Registry implantable cardioverter-defibrillator (ICD) registry da
116 tion Registry, and the Swedish Pacemaker and Implantable Cardioverter-Defibrillator (ICD) Registry.
117 (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in s
118 rictions for 3 to 6 months after appropriate implantable cardioverter-defibrillator (ICD) shocks, con
119 .5 tesla for patients who had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "n
120 Of the 118 ES patients, 21 had appropriate implantable cardioverter-defibrillator (ICD) therapy ter
121 failure (HF) to amiodarone, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy.
124 ypes of devices that include the transvenous implantable cardioverter-defibrillator (ICD) with or wit
125 y an automatic external defibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearabl
127 tion ECGs would predict arrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible ca
133 imaging (MRI) of patients with conventional implantable cardioverter-defibrillators (ICD) is contrai
134 art failure patients with primary prevention implantable cardioverter-defibrillators (ICD) may experi
136 any duration in patients with pacemakers and implantable cardioverter defibrillators (ICDs) and evalu
137 ergoing primary prophylactic implantation of implantable cardioverter defibrillators (ICDs) experienc
138 licting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for prima
140 at high SCD risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces m
141 The study group comprised 160 patients with implantable cardioverter defibrillators (ICDs), of whom
148 ted risk for sudden cardiac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the m
149 are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used
155 risk of atrial fibrillation in patients with implantable cardioverter-defibrillators (ICDs), but vent
156 t advances in management strategy, including implantable cardioverter-defibrillators (ICDs), heart tr
157 ufacturer-specific, strategic programming of implantable cardioverter-defibrillators (ICDs), includin
158 between 2008 and 2011 with pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), or cardi
164 retrospective cohort study of patients with implantable cardioverter-defibrillators identified from
165 h higher frequency of palpitation (P=0.004), implantable cardioverter defibrillator implantation (P=0
166 rience a significant complication related to implantable cardioverter defibrillator implantation in c
167 of patients who are the best candidates for implantable cardioverter defibrillator implantation is o
168 d this observation require further study but implantable cardioverter defibrillator implantation shou
170 risk of nonsudden death who may benefit from implantable cardioverter defibrillator implantation.
171 ho did not have a preexisting indication for implantable cardioverter defibrillator implantation.
172 ed cardiac magnetic resonance imaging before implantable cardioverter-defibrillator implantation for
173 is important for the decision making before implantable cardioverter-defibrillator implantation for
174 icular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a
175 may be a predictor of survival benefit after implantable cardioverter-defibrillator implantation in p
176 e assessed the Guideline recommendations for implantable cardioverter-defibrillator implantation in p
178 een HF quartiles (P=0.91), and the effect of implantable cardioverter-defibrillator implantation on a
179 of DFT versus no-DFT testing at the time of implantable cardioverter-defibrillator implantation was
180 llation efficacy at the time of subcutaneous implantable cardioverter-defibrillator implantation with
181 Of 314 patients who underwent subcutaneous implantable cardioverter-defibrillator implantation, 282
182 Outcome in index-patients was modulated by implantable cardioverter-defibrillator implantation, but
183 ch to the selection of patients with DCM for implantable cardioverter-defibrillator implantation.
184 may have direct impact on the indication of implantable cardioverter-defibrillator implantation.
185 utations is crucial to select candidates for implantable cardioverter-defibrillator implantation.
186 duration of HF, mode of death, and effect of implantable cardioverter-defibrillator implantation.
187 ith the use of a registry containing data on implantable cardioverter-defibrillator implantations fro
188 rent guidelines only recommend the use of an implantable cardioverter defibrillator in patients with
189 ration (>/=120 ms) receiving either CRT-D or implantable cardioverter defibrillator in subgroups acco
191 Danish Study to Assess the Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients Wit
193 the chest, nuclear procedures, and pacemaker/implantable cardioverter-defibrillator insertion and rep
194 terventions (1.0 to 2.4 per 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 t
195 ndpoint of sudden cardiac death, appropriate implantable cardioverter-defibrillator intervention, and
196 vice-related complications and inappropriate implantable cardioverter defibrillator interventions.
197 ed in 63 other high-risk patients (13%) with implantable cardioverter-defibrillator interventions for
200 Although for patients at increased risk an implantable cardioverter-defibrillator is recommended, i
202 A total of 80 VF events were recorded in the implantable cardioverter-defibrillator logs the 6 months
203 s, 44 patients received secondary prevention implantable cardioverter-defibrillators (long QT syndrom
204 ubcutaneous implantation of the subcutaneous implantable cardioverter-defibrillator may offer procedu
206 dysrhythmia by cardiac resynchronisation and implantable cardioverter-defibrillators; neurohumoral mo
207 ence of a permanent pacemaker rather than an implantable cardioverter-defibrillator (odds ratio, 3.90
208 F hospitalization or death with CRT-D versus implantable cardioverter-defibrillator only therapy, whe
211 Patients with persistent AF, dual-chamber implantable cardioverter defibrillator or cardiac resync
214 ds ratio [OR], 1.21 [95% CI, 1.17-1.25]), no implantable cardioverter defibrillator (OR, 1.46 [95% CI
215 uction in VT episodes (tracked by indwelling implantable cardioverter defibrillators) or any reductio
217 s to investigate the impact of an additional implantable cardioverter-defibrillator over CRT, accordi
218 o 26.8% (p < 0.0001); the frequency of VT in implantable cardioverter-defibrillator patients with rec
219 coronary artery bypass grafts, 2 epicardial implantable cardioverter defibrillator placement, 5 valv
220 required cardioversion in 2 patients and new implantable cardioverter-defibrillator placement in 2.
222 alone, this results in approximately 130 000 implantable cardioverter defibrillator placements at a c
224 m the National Cardiovascular Data Registry, implantable cardioverter-defibrillator registry between
225 -producing course for CIEDs, pacemakers, and implantable cardioverter-defibrillators, respectively.
226 ated with early adoption of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the Un
228 CM) ECG make it a challenge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening
230 2.8 [2.1-3.7]), and survivors more often had implantable cardioverter defibrillator's implanted (OR,
231 nsidering the competing risks of appropriate implantable cardioverter defibrillator shock versus mort
234 nd point including death, HT, or appropriate implantable cardioverter-defibrillator shock were assess
238 tation; n=6 with previous cardiac arrest and implantable cardioverter defibrillator shocks for ventri
242 Radiofrequency catheter ablation reduced implantable cardioverter-defibrillator shocks and VT epi
243 recurrence; the proportion of patients with implantable cardioverter-defibrillator shocks decreased
244 rphic ventricular tachycardia requiring >/=2 implantable cardioverter-defibrillator shocks occurred i
247 SCD, aborted cardiac arrest, and appropriate implantable cardioverter-defibrillator shocks) was 0.84
248 opriate ventricular fibrillation-terminating implantable cardioverter-defibrillator shocks, and sudde
251 ecurrences of VT were defined as appropriate implantable cardioverter defibrillator therapies or on t
253 ion 30%) were studied (6 month preprocedural implantable cardioverter defibrillator therapies: median
254 lated to higher risk of mortality or HF with implantable cardioverter defibrillator therapy alone.
255 Women are less likely to be referred for implantable cardioverter defibrillator therapy despite c
256 proportion of patients received appropriate implantable cardioverter defibrillator therapy during me
257 ation, sudden cardiac death, and appropriate implantable cardioverter defibrillator therapy was noted
258 out-of-hospital cardiac arrest, appropriate implantable cardioverter defibrillator therapy, and sudd
263 I(2)=0%; high-quality evidence), appropriate implantable cardioverter-defibrillator therapy (5 studie
264 predicted to have an attenuated benefit from implantable cardioverter-defibrillator therapy (older ad
265 predicts long-term mortality and appropriate implantable cardioverter-defibrillator therapy in ischem
266 his disease, it is also well recognized that implantable cardioverter-defibrillator therapy is associ
267 n remains challenging because the benefit of implantable cardioverter-defibrillator therapy may not b
269 t benefit from additional primary prevention implantable cardioverter-defibrillator therapy, as oppos
270 point was a composite of SCD and appropriate implantable cardioverter-defibrillator therapy, identica
271 ac events (sudden cardiac death, appropriate implantable cardioverter-defibrillator therapy, resuscit
272 ion of primary combined outcome (appropriate implantable cardioverter-defibrillator therapy, survived
277 THODS AND Pigs implanted with single-chamber implantable cardioverter defibrillators to record ventri
278 ined VA (>=30s, hemodynamically unstable, or implantable cardioverter-defibrillator treated ventricul
279 s with LTVA (SCD, aborted SCD, sustained, or implantable cardioverter-defibrillator treated ventricul
280 s defined as (1) sudden cardiac death or (2) implantable cardioverter defibrillator-treated or hemody
281 ac magnetic resonance assessment may improve implantable cardioverter-defibrillator treatment decisio
283 nts with a clinical diagnosis of CPVT and an implantable cardioverter-defibrillator underwent a basel
284 w incidence of SCD and a low rate of primary implantable cardioverter-defibrillator utilization in pa
285 o, 1.50 [CI, 1.13-1.99], P<0.01) but neither implantable cardioverter-defibrillator utilization nor v
286 pite a low rate (4.0%) of primary prevention implantable cardioverter-defibrillator utilization.
288 n men, the lower mortality with CRT-D versus implantable cardioverter defibrillator was less pronounc
291 ith longer duration of HF, and the effect of implantable cardioverter-defibrillator was not modified
292 therapy with defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was associated w
293 that in LBBB patients, CRT-D, compared with implantable cardioverter-defibrillator, was associated w
294 ction </=35% referred for primary prevention implantable cardioverter defibrillator, we developed dua
297 th BrS, median age 39 years (30.3-42.3) with implantable cardioverter-defibrillator were enrolled.
299 23 patients (29%) of 78 IVF patients with an implantable cardioverter-defibrillator, with a median of
300 leads, and dependence on a pacemaker with an implantable cardioverter defibrillator without asynchron